Laboratory Assessment of the Anticoagulant Activity of Dabigatran

Clinical and Applied Thrombosis/Hemostasis

Volumn 21, Issue 5, 2015, Pages 434-445

  Kyriakou, Elias ^a   Ikonomidis, Ignatios ^a   Stylos, Dimitrios ^a   Bonovas, Stefanos ^b   Papadakis, Ioannis ^a   Nikolopoulos, Georgios K ^c,d   Kokoris, Styliani ^a   Kalantzis, Dimitrios ^a   Economopoulou, Christine ^a   Kopterides, Petros ^a   Lekakis, John ^a   Tsantes, Argirios E ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^d Hellenic Centre for Disease Control and Prevention   (Greece)

Author keywords

anticoagulants; cardiology; hemostasis

Indexed keywords

ACENOCOUMAROL; ADRENALIN; DABIGATRAN ETEXILATE; THROMBIN; THROMBIN INHIBITOR; ANTITHROMBIN; DABIGATRAN;

ADULT; AGED; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; ATRIAL FIBRILLATION; BLOOD ANALYSIS EQUIPMENT; BLOOD CLOTTING TEST; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; LABORATORY TEST; LYSIS; MALE; PRIORITY JOURNAL; BLOOD CLOTTING; DEVICES; DRUG EFFECTS;

AGED; ANTITHROMBINS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DABIGATRAN; FEMALE; HUMANS; MALE;

EID: 84933034549     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029614564209     Document Type: Article

References (33)

1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-RY steering committee and investigators: dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 ; 361 ((12)). 1139
2. Bauer KA. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost. 2011 ; 9 ((suppl 1)). 12
3. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007 ; 98 ((1)). 155
4. Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban, and apixaban in preclinical and clinical development. Thromb Haemost. 2010 ; 103 ((3)). 572
5. Legrand M, Mateo J, Aribouad A, et al. The use of dabigatran in elderly patients. Arch Int Med. 2011 ; 171 ((14)). 1285
6. Tripodi A. Laboratory tests and the new oral anticoagulants. Thromb Res. 2012 ; 130 ((suppl 1)). 95
7. Samama MM, Guinet C, Le Flem L. Do new oral anticoagulants require laboratory monitoring? The clinician point of view. Thromb Res. 2012 ; 130 ((suppl 1)). S88 - S89
8. Hoffman M, Monroe DM. Coagulation 2006: a modern view of hemostasis. Hematol Oncol Clin North Am. 2007 ; 21 ((1)). 1-11
9. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest. 1995 ; 96 ((5)). 2534
10. Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010 ; 103 ((6)). 1116
11. Harenberg J, Giese C, Marx S, Krämer R. Determination of dabigatran in human plasma samples. Semin Thromb Hemost. 2012 ; 38 ((1)). 16
12. Douxfils J, Mullier F, Robert S, et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost. 2012 ; 107 ((5)). 985-997
13. Halbmayer W, Weigel G, Quehenberger P, et al. Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Clin Chem Lab Med. 2012 ; 50 ((9)). 1601
14. Avecilla S, Ferrell C, Chandler W, Reyes M. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol. 2012 ; 137 ((4)). 572-574
15. Green L, Lawrie AS, Patel R, et al. The effect of total hip/knee replacement surgery and prophylactic dabigatran on thrombin generation and coagulation parameters. Thromb Res. 2012 ; 130 ((5)). 775-779
16. Hapgood G, Butler J, Malan E, Chunilal S, Tran H. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost. 2013 ; 110 ((2)). 308-315
17. Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran. N Engl J Med. 2011 ; 365 ((21)). 2039-2040
18. Eikelboom JW, Weitz JI. More on acutely injured patients receiving dabigatran. N Engl J Med. 2012 ; 366 ((9)). 863
19. Sipahi I, Celik S, Tozun N. A comparison of results of the US Food and Drug Administration's Mini-Sentinel program with randomized clinical trials: the case of gastrointestinal tract bleeding with dabigatran. JAMA Intern Med. 2014 ; 174 ((1)). 150
20. Cohen D. Dabigitran: how the drug company withheld important analyses. BMJ. 2014 ; 349: g4670
21. Love JE, Ferrell C, Chandler WL. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost. 2007 ; 98 ((1)). 234-242
22. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012 ; 23 ((2)). 138
23. Tsantes AE, Mantzios G, Giannopoulou V, et al. Monitoring aspirin treatment in patients with thrombocytosis: comparison of the platelet function analyzer (PFA)-100 with optical aggregometry. Thromb Res. 2008 ; 123 ((1)). 100-107
24. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-term Anticoagulant Therapy (RE-LY) trial. Circulation. 2011 ; 123 ((21)). 2363
25. Charlton B, Redberg R. The trouble with dabigatran. BMJ. 2014 ; 349: g4681
26. Al Dieri R, Hemker HC. Monitoring new oral antithrombotics: what we should know before we can decide. J Thromb Haemost. 2010 ; 8 ((12)). 2833
27. Dale B, Eikelboom JW, Weitz JI, et al. Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?. J Thromb Thrombolysis. 2013 ; 35 ((2)). 295
28. Wagenvoord RJ, Deinum J, Elg M, Hemker HC. The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by alpha-macroglobulin-thrombin. J Thromb Haemost. 2010 ; 8 ((6)). 1281
29. Perzborn E, Heitmeier S, Buetehorn U, et al. Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo. J Thromb Haemost. 2014 ; 12 ((7)). 1054-1065
30. Douxfils J, Buckinx F, Mullier F, et al. Dabigatran Etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2014 ; 3 (3). e000515
31. Larsen TB, Rasmussen LH, Skjøth F, et al. Efficacy and safety of Dabigatran Etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol. 2013 ; 61 ((22)). 2264-2273
32. Dinkelaar J, Patiwael S, Harenberg J, Leyte A, Brinkman HJ. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate. Clin Chem Lab Med. 2014 ; 52 ((11)). 1615-1623
33. Herrmann R, Thom J, Wood A, et al. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost. 2014 ; 111 ((5)). 989-995